Boston Common Asset Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $210K | Sell |
3,804
-292
| -7% | -$15.8K | 0.01% | 181 |
|
|
2025
Q4 | $201K | Buy |
+4,096
| New | +$191K | 0.01% | 190 |
|
|
2024
Q1 | – | Sell |
-24,158
| Closed | -$895K | – | 305 |
|
|
2023
Q4 | $895K | Sell |
24,158
-10
| -0% | -$359 | 0.02% | 266 |
|
|
2023
Q3 | $876K | Sell |
24,168
-5,670
| -19% | -$201K | 0.02% | 258 |
|
|
2023
Q2 | $1.06M | Hold |
29,838
| – | – | 0.02% | 256 |
|
|
2023
Q1 | $1.06M | Buy |
29,838
+65
| +0.2% | +$2.27K | 0.02% | 254 |
|
|
2022
Q4 | $1.05M | Hold |
29,773
| – | – | 0.05% | 161 |
|
|
2022
Q3 | $876K | Buy |
29,773
+5,250
| +21% | +$199K | 0.05% | 170 |
|
|
2022
Q2 | $1.33M | Buy |
24,523
+4,232
| +21% | +$234K | 0.07% | 161 |
|
|
2022
Q1 | $1.1M | Buy |
20,291
+4
| +0% | +$217 | 0.05% | 169 |
|
|
2021
Q4 | $1.12M | Sell |
20,287
-24
| -0.1% | -$1.25K | 0.05% | 167 |
|
|
2021
Q3 | $970K | Sell |
20,311
-595,224
| -97% | -$29.9M | 0.04% | 169 |
|
|
2021
Q2 | $30.6M | Buy |
615,535
+10,353
| +2% | +$497K | 1.32% | 24 |
|
|
2021
Q1 | $27M | Buy |
605,182
+71,355
| +13% | +$3.24M | 1.7% | 8 |
|
|
2020
Q4 | $24.6M | Buy |
533,827
+10,425
| +2% | +$479K | 1.71% | 10 |
|
|
2020
Q3 | $24.6M | Buy |
523,402
+21,607
| +4% | +$1.08M | 2.34% | 6 |
|
|
2020
Q2 | $25.6M | Buy |
501,795
+35,277
| +8% | +$1.81M | 2.73% | 5 |
|
|
2020
Q1 | $22.1M | Buy |
+466,518
| New | +$24.9M | 3.12% | 4 |
|
|
2017
Q4 | – | Sell |
-8,356
| Closed | -$424K | – | 187 |
|
|
2017
Q3 | $424K | Hold |
8,356
| – | – | 0.05% | 167 |
|
|
2017
Q2 | $450K | Hold |
8,356
| – | – | 0.06% | 163 |
|
|
2017
Q1 | $440K | Sell |
8,356
-1,936
| -19% | -$98.2K | 0.06% | 163 |
|
|
2016
Q4 | $495K | Hold |
10,292
| – | – | 0.07% | 158 |
|
|
2016
Q3 | $555K | Sell |
10,292
-1,040
| -9% | -$57K | 0.03% | 235 |
|
|
2016
Q2 | $614K | Sell |
11,332
-83,775
| -88% | -$4.41M | 0.04% | 226 |
|
|
2016
Q1 | $4.82M | Sell |
95,107
-5,740
| -6% | -$286K | 0.27% | 114 |
|
|
2015
Q4 | $5.09M | Sell |
100,847
-13,304
| -12% | -$678K | 0.29% | 108 |
|
|
2015
Q3 | $5.49M | Sell |
114,151
-3,523
| -3% | -$183K | 0.33% | 102 |
|
|
2015
Q2 | $6.13M | Sell |
117,674
-4,368
| -4% | -$246K | 0.32% | 100 |
|
|
2015
Q1 | $7.04M | Sell |
122,042
-968
| -0.8% | -$55.5K | 0.38% | 96 |
|
|
2014
Q4 | $6.57M | Buy |
123,010
+1,268
| +1% | +$70.9K | 0.37% | 100 |
|
|
2014
Q3 | $7M | Buy |
121,742
+5,828
| +5% | +$357K | 0.39% | 96 |
|
|
2014
Q2 | $7.75M | Sell |
115,914
-1,360
| -1% | -$92.1K | 0.42% | 91 |
|
|
2014
Q1 | $7.83M | Sell |
117,274
-6,808
| -5% | -$460K | 0.44% | 89 |
|
|
2013
Q4 | $8.28M | Buy |
124,082
+20,412
| +20% | +$1.32M | 0.46% | 86 |
|
|
2013
Q3 | $6.5M | Sell |
103,670
-3,938
| -4% | -$253K | 0.38% | 106 |
|
|
2013
Q2 | $6.72M | Buy |
+107,608
| New | +$6.83M | 0.42% | 100 |
|
Other funds holding GSK
JEST
Boston Common Asset Management's GSK Position: Q1 2026 in Review
Boston Common Asset Management reduced its GSK (GSK) stake by 7.1% in Q1 2026, selling an estimated $15.8K and leaving 3,804 shares worth $210K. The position accounts for 0.01% of the portfolio, ranked #181.
Boston Common Asset Management first reported a position in GSK in Q2 2013 and has held it in 36 quarters since. The position peaked at $30.6M in Q2 2021. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Boston Common Asset Management held 3,804 shares of GSK worth $210K as of Q1 2026.
- Boston Common Asset Management sold 292 GSK shares in Q1 2026, an estimated $15.8K.
- GSK made up 0.01% of Boston Common Asset Management's portfolio in Q1 2026, its #181 holding.
- Boston Common Asset Management first reported a position in GSK in Q2 2013 and has held it in 36 quarters since.
- Boston Common Asset Management's GSK position peaked at $30.6M in Q2 2021.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Boston Common Asset Management's 13F filing for Q1 2026, filed 7 May 2026.